When It Comes To Complex PTSD, Depression, Research Turns to Psychedelics For Treatment

People struggling with treatment-resistant PTSD may soon have a new
course of care: MDMA. When used alongside psychotherapy, the
synthetic substance in the drug more commonly known as ecstasy or
molly is currently in phase three clinical trials. It’s even been
given “breakthrough designation” by the FDA, a status reserved for
treatments with significant potential to improve patient outcomes.
But MDMA isn’t the only kind of party drug experiencing interest
for therapeutic potential. Psilocybin, the active ingredient in
"magic mushrooms", is being evaluated for its potential in
alleviating depression. Guided ayahuasca trips are a growing trend,
especially amongst Brooklyn and Silicon Valley elites.